PT  - JOURNAL ARTICLE
AU  - ELENA ORTONA
AU  - SILVIA L. LOCATELLI
AU  - MARIA TERESA PAGANO
AU  - BARBARA ASCIONE
AU  - GIUSEPPA CAREDDU
AU  - MARIA LUISA DUPUIS
AU  - MATTEO MARCONI
AU  - CARMELO CARLO-STELLA
AU  - WALTER MALORNI
AU  - PAOLA MATARRESE
AU  - MARINA PIERDOMINICI
TI  - The Natural Estrogen Receptor Beta Agonist Silibinin as a Promising Therapeutic Tool in Diffuse Large B-cell Lymphoma
AID  - 10.21873/anticanres.15535
DP  - 2022 Feb 01
TA  - Anticancer Research
PG  - 767--779
VI  - 42
IP  - 2
4099  - http://ar.iiarjournals.org/content/42/2/767.short
4100  - http://ar.iiarjournals.org/content/42/2/767.full
SO  - Anticancer Res2022 Feb 01; 42
AB  - Background/Aim: About 40% of patients with diffuse large cell lymphoma (DLBCL) still have a poor prognosis. Additionally, DLBCL patients treated with doxorubicin are at risk of cardiac failure. Growing evidence suggests an antitumor and cardioprotective activity exerted by estrogen via its binding to estrogen receptor (ER) β. The aim of this study was to evaluate the anticancer activity of the phytoestrogen silibinin, an ERβ selective agonist, on DLBCL growth, and its potential cardioprotective effect. Materials and Methods: DLBCL cell lines SUDHL-8, SUDHL-6, and RIVA were used. The anti-tumor activity of silibinin was also evaluated in vivo in NOD/SCID/IL2Rg–/– (NSG) xenografted mice. AC16 human ventricular cardiomyocytes were used to investigate the cardioprotective effects of silibinin. Results: In vitro silibinin induced apoptosis and autophagy, and blocked tumor cell proliferation, also protecting AC16 cardiomyocytes from doxorubicin-induced toxicity. In vivo silibinin induced cell death and autophagy, and reduced tumor volume. Conclusion: Silibinin represents a promising therapeutic tool.